文献速递肝病

ADAPT:一种纳入PRO-C3的算法能准确识别非酒精性脂肪性肝病合并进展性肝纤维化患者

ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.
PubMed 文献 · Hepatology · 2019-01-01

在150例推导队列和281例验证队列中,基于PRO-C3、年龄、糖尿病和血小板计数的ADAPT算法对进展性肝纤维化(≥F3)的受试者工作特征曲线下面积分别为0.86和0.87,多数比较中优于APRI、FIB-4和NFS。PRO-C3随纤维化分期升高且为进展性肝纤维化的独立预测因子。

要点

  • PRO-C3随纤维化分期升高(Rho 0.50;P < 0.0001),为进展性肝纤维化的独立预测因子。
  • ADAPT对进展性肝纤维化的AUROC在推导队列为0.86、验证队列为0.87。
  • ADAPT在多数比较中优于APRI、FIB-4和NFS。

核心结论

  • PRO-C3是非酒精性脂肪性肝病纤维化分期的独立预测因子。
  • 基于PRO-C3的ADAPT评分能准确识别非酒精性脂肪性肝病合并进展性肝纤维化,且优于APRI、FIB-4和NFS。

研究设计与样本

  • 在推导队列150例和验证队列281例具有详细临床表型及肝活检的大型独立队列中,用酶联免疫吸附试验测定PRO-C3。
  • 开发了纳入年龄、糖尿病有无、PRO-C3和血小板计数的基于PRO-C3的纤维化算法ADAPT。

主要发现

  • PRO-C3随纤维化分期升高(Rho 0.50;P < 0.0001)。
  • PRO-C3与进展性肝纤维化独立相关(比值比 = 1.05;95%置信区间 1.02-1.08;P = 0.003)。
  • ADAPT对进展性肝纤维化的受试者工作特征曲线下面积在推导队列为0.86(95%置信区间 0.79-0.91),在验证队列为0.87(95%置信区间 0.83-0.91)。
  • ADAPT在多数比较中优于现有纤维化评分APRI、FIB-4和NFS。

关键数值与推荐

  • 进展性肝纤维化定义为≥ F3。
  • ADAPT算法组成:年龄、糖尿病有无、PRO-C3、血小板计数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given the high global prevalence of nonalcoholic fatty liver disease (NAFLD), the need for relevant noninvasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need. Identifying those with advanced fibrosis (≥ F3) is the most crucial, as these individuals have the greatest risk of adverse, long-term, liver-related outcomes. We aimed to investigate the role of PRO-C3 (a marker of type III collagen formation) as a biomarker for advanced fibrosis in NAFLD. We measured PRO-C3 by enzyme-linked immunosorbent assay in two large independent cohorts with extensive clinical phenotyping and liver biopsy: 150 in the derivation and 281 in the validation cohort. A PRO-C3-based fibrosis algorithm that included age, presence of diabetes, PRO-C3, and platelet count (ADAPT) was developed. PRO-C3 increased with fibrosis stage (Rho 0.50; P < 0.0001) and was independently associated with advanced fibrosis (odds ratio = 1.05; 95% confidence interval [CI] 1.02-1.08; P = 0.003). ADAPT showed areas under the receiver operating characteristics curve of 0.86 (95% CI 0.79-0.91) in the derivation and 0.87 in the validation cohort (95% CI 0.83-0.91) for advanced fibrosis. This was superior to the existing fibrosis scores, aspartate aminotransferase to platelet ratio index (APRI), FIB-4, and NAFLD fibrosis score (NFS) in most comparisons. Conclusion: PRO-C3 is an independent predictor of fibrosis stage in NAFLD. A PRO-C3-based score (ADAPT) accurately identifies patients with NAFLD and advanced fibrosis and is superior to APRI, FIB-4, and NFS.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology. 2019. PMID: 30014517. doi:10.1002/hep.30163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。